Jubilant Ingrevia Limited (JUBLINGREA.NS)
INR 800.95
(-4.21%)
INR 800.95
(-4.21%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.25 Billion INR | 171.08% |
| 2022 | 1.56 Billion INR | 47.59% |
| 2021 | 1.06 Billion INR | -77.07% |
| 2020 | 4.63 Billion INR | 0.0% |
| 2019 | - INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 3.85 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 4.25 Billion INR | 171.08% |
| 2023 Q4 | 4.25 Billion INR | 0.0% |
| 2023 Q2 | 3.05 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 65.8 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 1.56 Billion INR | 47.59% |
| 2022 Q4 | 1.56 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 1.06 Billion INR | -77.07% |
| 2021 Q4 | 1.06 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 1.92 Billion INR | 0.0% |
| 2020 FY | 4.63 Billion INR | 0.0% |
| 2020 Q4 | 4.63 Billion INR | 0.0% |
| 2020 Q3 | - INR | 0.0% |
| 2019 FY | - INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Biocon Limited | 129.32 Billion INR | 96.709% |
| Blue Jet Healthcare Limited | 3.79 Million INR | -112187.599% |
| Concord Biotech Limited | 18.87 Million INR | -22452.729% |
| Dishman Carbogen Amcis Limited | 2.45 Billion INR | -73.271% |
| Lyka Labs Limited | 429.06 Million INR | -891.85% |
| Panacea Biotec Limited | 209.9 Million INR | -1927.489% |
| Piramal Pharma Limited | 24.83 Billion INR | 82.866% |
| SMS Lifesciences India Limited | 331.45 Million INR | -1183.964% |
| Supriya Lifescience Limited | 50.2 Million INR | -8377.49% |
| Syngene International Limited | 1 Billion INR | -325.57% |
| TAKE Solutions Limited | 7.5 Million INR | -56642.667% |
| Zota Health Care Limited | 631.64 Million INR | -573.752% |